/
PBH
$48.03-$1.38 (-2.79%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.3B
47M shares
52-week range
$42.62 – $81.65
14% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $975.8M | $963.0M | $943.4M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B |
| Cost of revenue | $420.2M | $410.8M | $395.9M | $466.2M | $502.4M | $500.9M | $503.3M | $514.1M |
| Gross profit | $555.6M | $552.2M | $547.5M | $620.6M | $625.3M | $624.4M | $634.5M | $574.6M |
| Gross margin | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 52.8% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $67.5M | $291.2M | $297.4M | $329.9M | −$22.4M | $342.4M | $336.8M | $309.4M |
| EBITDA | $98.8M | $325.5M | $316.6M | $358.8M | $7.9M | $373.9M | $362.0M | $331.1M |
| Net income | −$35.8M | $142.3M | $164.7M | $205.4M | −$82.3M | $209.3M | $214.6M | $190.3M |
| Net margin | -3.7% | 14.8% | 17.5% | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| EPS (diluted) | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | 3.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $1.2B | $4.54 | $4.51–$4.56 | 3 |
| 2028 | $1.3B | $4.90 | $4.81–$4.99 | 3 |
| 2029 | $1.4B | $5.38 | $4.95–$5.56 | 1 |
| 2030 | $1.4B | $5.62 | $5.18–$5.81 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$367.84
Price
$48.03
Implied upside
+666%
Peer comparison
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
www.prestigebrands.com- Employees
- 890
- IPO / List date
- Feb 10, 2005
- HQ
- TARRYTOWN, NY
Held by traders on TradeandTell
No one on the platform currently holds PBH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 36,702 | $2.2M |
| Bridgewater Associatesas of 2025-09-30 | 9,657 | $602.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PBH yet.
